Male Reproductive Health

Stem Cell Therapy for Male Infertility in 2026

How mesenchymal stem cell therapy is being explored for non-obstructive azoospermia, severe oligospermia, and idiopathic male infertility — and what the 2026 evidence supports.

13 min read

Educational

Ultimo aggiornamento: 5 febbraio 2026

Revisionato medicalmente da Team Medico SCL

Summarize with AI:

Male Infertility in 2026

Male factor accounts for approximately 40-50% of infertility cases globally. The spectrum ranges from minor abnormalities in sperm count, motility, or morphology that respond to lifestyle and IVF/ICSI to severe conditions like non-obstructive azoospermia (NOA), where no sperm are present in the ejaculate due to impaired spermatogenesis. Conventional treatment in 2026 includes lifestyle optimisation, varicocele repair, hormonal therapy in selected hypogonadal patients, surgical sperm retrieval (TESE, micro-TESE) combined with IVF/ICSI, and donor sperm for patients in whom no sperm can be retrieved.

For men with severe spermatogenesis impairment, particularly non-obstructive azoospermia, conventional options have significant limits. Micro-TESE successfully retrieves sperm in only 40-60% of NOA patients, with significant variability based on aetiology. For those without successful retrieval, donor sperm is often the only path to biological-genetic parenthood. The desire for treatments that might restore endogenous spermatogenesis has driven significant interest in regenerative medicine.

Mesenchymal stem cell therapy is being explored as an emerging adjunctive option for selected male infertility conditions. The biological rationale is strongest for conditions involving testicular inflammation, microvascular dysfunction, and damaged but not absent germinal epithelium. Evidence is earlier-stage than for many other indications, with multiple Phase 1/2 trials underway in 2026.

How MSCs May Support Male Reproductive Function

MSCs target multiple mechanisms relevant to spermatogenesis and testicular function.

Testicular Inflammation

Chronic low-grade testicular inflammation contributes to impaired spermatogenesis. MSCs powerfully reduce inflammatory cytokines in the testicular microenvironment.

Sertoli Cell Support

Sertoli cells provide the structural and biochemical support for developing sperm. MSC-secreted factors may help restore Sertoli cell function.

Microvascular Repair

Testicular blood flow and microvascular health are essential for spermatogenesis. MSCs support microvascular preservation and repair.

Hormonal Modulation

MSCs may indirectly support Leydig cell function and testosterone production in selected cases of dysfunctional steroidogenesis.

Sperm Quality

In oligospermia patients, MSC therapy may modestly improve sperm count, motility, and morphology over 3-6 months in responders.

Stem Cell Niche

MSCs may help restore the testicular stem cell niche that supports endogenous spermatogonial stem cells, potentially relevant in some forms of NOA.

Male Reproductive Conditions That May Respond

Conditions with the most plausible biological case for MSC therapy in 2026.

Severe oligospermia with sperm present but markedly reduced count

Asthenozoospermia (poor motility) and teratozoospermia (poor morphology)

Selected cases of non-obstructive azoospermia where some germinal epithelium remains

Post-varicocelectomy patients with persistent sperm parameter abnormalities

Idiopathic male factor infertility without identified cause

Post-chemotherapy or post-radiation testicular damage in cancer survivors

Mild hypogonadism with low-normal testosterone and impaired spermatogenesis

Recurrent IVF/ICSI failure with male factor component

What the Clinical Evidence Shows

Clinical evidence for MSC therapy in male infertility is earlier-stage than for many other indications. Multiple Phase 1/2 trials, primarily from Iranian, Chinese, and European centres, have shown safety and encouraging biomarker signals — improvements in sperm count, motility, and morphology in oligospermia patients, and in some published cases, return of sperm to the ejaculate in selected NOA patients (a remarkable but uncommon outcome). Hormonal markers including FSH and testosterone have shown modest improvements in some series.

The strongest signals have been in patients with severe oligospermia rather than complete azoospermia, in younger patients, and in those whose testicular impairment has an inflammatory or microvascular component rather than complete germinal aplasia. For Sertoli-cell-only syndrome and other forms of complete spermatogenic failure, the realistic potential for restoration is much lower.

The 2026 honest summary is that MSC therapy may modestly improve sperm parameters in selected oligospermia patients and in rare cases produce sperm in NOA patients who previously had none, but should not be presented as a reliable solution for severe male infertility. Donor sperm and adoption remain important options for couples for whom restoration of endogenous spermatogenesis is not realistic.

Treatment Protocol

Protocols for male infertility typically combine intravenous MSC infusion with direct intratesticular injection in selected cases. IV infusion provides systemic anti-inflammatory effect; direct injection delivers high local concentration to the testicular tissue. Cell doses are individualised. Most patients receive 1-2 IV infusions and, when intratesticular injection is included, 1-2 injections per testis.

Pre-treatment evaluation includes detailed semen analysis (recent and historical), hormonal profile (FSH, LH, testosterone, prolactin, oestradiol), genetic screening if not already performed (Y-chromosome microdeletions, karyotype), scrotal ultrasound, and review of any prior surgical interventions or treatments. The protocol is coordinated with the patient's urologist or reproductive specialist whenever possible.

The procedures are well tolerated. IV infusion is outpatient. Intratesticular injection is performed under local anaesthesia with appropriate sterile technique. Most patients return to work within 1-2 days. Effects on sperm parameters develop over 2-3 spermatogenesis cycles (approximately 3 months per cycle), with serial semen analysis at 3, 6, and 12 months tracking response.

Integration with Reproductive Medicine

MSC therapy works alongside, not instead of, established male infertility care.

Urology Coordination

Your urologist or andrologist should remain central. MSC therapy is adjunctive, designed to improve the underlying biology that conventional treatments work with.

Lifestyle Foundations

Smoking cessation, alcohol moderation, weight management, heat exposure reduction, and supplement optimisation remain foundational and amplify any MSC therapy effect.

Varicocele Management

If a clinically significant varicocele is present, surgical repair should typically precede or accompany MSC therapy.

Hormonal Optimisation

Where indicated, hormonal therapy (clomiphene, hCG, FSH) may be used in conjunction with MSC therapy.

Realistic Timing

Improvements in sperm parameters develop over 3-9 months across multiple spermatogenesis cycles.

IVF/ICSI Planning

If IVF/ICSI is planned, MSC therapy is typically performed 3-6 months before the planned cycle to maximise the chance of improved sperm quality.

Suitability Considerations

Honest patient selection protects couples from inappropriate expectations.

Confirmed male infertility diagnosis with full workup

Some preserved spermatogenesis or plausible biological basis for restoration

Realistic expectations: improvement in parameters or chance of sperm retrieval, not guaranteed natural conception

Willing to coordinate with home urology and reproductive medicine team

Foundational lifestyle factors addressed

Genetic causes (Y-chromosome microdeletions, etc.) understood — these significantly affect prognosis

No active malignancy or significant medical contraindication

Honest discussion of when donor sperm may be the more realistic option

Frequently Asked Questions

In a small number of published cases, yes — patients with NOA have shown return of sperm to the ejaculate after MSC therapy. However, this is uncommon and depends significantly on the underlying cause and the degree of preserved germinal epithelium. Patients with Sertoli-cell-only syndrome, complete germinal aplasia, or significant Y-chromosome microdeletions are unlikely to benefit. We are honest with patients about realistic expectations rather than over-promising restoration.

Spermatogenesis takes approximately 3 months per complete cycle, so meaningful changes in sperm parameters take 3-9 months to develop. Most clinical protocols include serial semen analysis at 3, 6, and 12 months after treatment. Patients hoping for immediate change should adjust expectations — this is gradual biological tissue effect, not a quick intervention.

The decision depends on individual circumstances. For patients with marginal cases of NOA, some specialists prefer MSC therapy first to potentially improve the chance of successful sperm retrieval. For patients with strong indication for immediate retrieval, micro-TESE may proceed first with MSC therapy considered later if needed. The decision should be made jointly with your urologist and reproductive specialist based on age, female partner age, and individual factors.

Performed under local anaesthesia by an experienced specialist, the procedure is well tolerated. Patients may experience mild discomfort during the injection itself and mild scrotal discomfort for 1-3 days afterward, similar to that following testicular biopsy. Serious complications such as significant bleeding or infection are uncommon. Most patients return to work within 1-2 days and to normal activity within a week.

In some patients with subclinical or mild hypogonadism, modest improvements in testosterone have been observed in published series, likely through anti-inflammatory effects on Leydig cells. However, MSC therapy is not a substitute for testosterone replacement therapy in patients who require it. Patients on existing testosterone therapy should not stop their treatment to attempt MSC therapy alone — testosterone therapy itself suppresses spermatogenesis and should be discontinued in patients trying to conceive regardless of any cellular therapy.

We offer combined IV infusion and selected intratesticular injection protocols with allogeneic Wharton's jelly MSCs, performed in coordination with our urology partners. Pre-arrival case review, in-house procedures, and structured 12-month follow-up coordinated with your home reproductive team are included. We are honest about likely benefit and discuss alternative paths (donor sperm) when realistic. Request a free consultation for an individualised assessment.

Continue Your Research

Discuss Your Male Infertility Case with a Specialist

Our team will review your reproductive workup and tell you honestly whether MSC therapy is likely to add meaningful value to your treatment path.

Coordinamento Internazionale dei Pazienti

StemCell Longevita opera come piattaforma di coordinamento internazionale dei pazienti. Mettiamo in contatto i pazienti con istituzioni mediche autorizzate che offrono applicazioni di medicina rigenerativa dopo valutazione medica e nel rispetto dei quadri normativi applicabili. Tutte le decisioni e le procedure mediche sono condotte esclusivamente da professionisti sanitari autorizzati. StemCell Longevita non fornisce direttamente trattamenti medici.

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as medical advice. Stem cell therapy is an evolving field, and outcomes may vary by individual. The treatments described on this site have not been fully evaluated or approved by the FDA or equivalent regulatory bodies in all jurisdictions.

The FDA has not approved stem cell applications for most conditions listed on this website. Results mentioned are based on clinical observations, published research, and patient-reported outcomes. Individual results may vary and no specific outcomes are assured for any individual patient.

L'inclusione di pubblicazioni scientifiche su questo sito non implica approvazione normativa o risultati clinici garantiti. Alcune applicazioni possono essere considerate sperimentali a seconda dell'indicazione e della giurisdizione.

Always consult with a qualified healthcare professional before making any medical decisions. Do not disregard professional medical advice or delay seeking treatment based on information found on this website.